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A B S T R A C T
Purpose
Few therapeutic options are available for patients with Philadelphia chromosome–positive (Ph1)
B-precursor acute lymphoblastic leukemia (ALL) who progress after failure of tyrosine kinase in-
hibitor (TKI) 2based therapy. Here, we evaluated the efﬁcacy and tolerability of blinatumomab in
patients with relapsed or refractory Ph1 ALL.
Patients and Methods
This open-label phase II study enrolled adults with Ph1 ALL who had relapsed after or were re-
fractory to at least one second-generation or later TKI or were intolerant to second-generation or later
TKIs and intolerant or refractory to imatinib. Blinatumomab was administered in 28-day cycles by
continuous intravenous infusion. The primary end point was complete remission (CR) or CR with
partial hematologic recovery (CRh) during the ﬁrst two cycles. Major secondary end points included
minimal residual disease response, rate of allogeneic hematopoietic stem-cell transplantation,
relapse-free survival, overall survival, and adverse events (AEs).
Results
Of 45 patients, 16 (36%; 95% CI, 22% to 51%) achieved CR/CRh during the ﬁrst two cycles,
including four of 10 patients with the T315I mutation; 88% of CR/CRh responders achieved
a complete minimal residual disease response. Seven responders (44%) proceeded to allogeneic
hematopoietic stem-cell transplantation, including 55% (six of 11) of transplantation-naı¨ve re-
sponders. Median relapse-free survival and overall survival were 6.7 and 7.1 months, respectively.
The most frequent AEs were pyrexia (58%), febrile neutropenia (40%), and headache (31%). Three
patients had cytokine release syndrome (all grade 1 or 2), and three patients had grade 3 neurologic
events, one of which (aphasia) required temporary treatment interruption. There were no grade 4 or
5 neurologic events.
Conclusion
Single-agent blinatumomab showed antileukemia activity in high-risk patientswith Ph1ALLwho had
relapsed or were refractory to TKIs. AEs were consistent with previous experience in Ph– ALL.
J Clin Oncol 35:1795-1802. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Philadelphia chromosome2positive (Ph1) acute
lymphoblastic leukemia (ALL) constitutes ap-
proximately 25% of adult B-precursor ALL and is
characterized by a reciprocal t(9;22) translocation
that generates a chimeric fusion protein, BCR-
ABL1, with dysregulated tyrosine kinase activity.
The presence of the Philadelphia chromosome has
historically been associated with a very poor
prognosis, but response and survival outcomes
have signiﬁcantly improved over the last decade.
The addition of targeted tyrosine kinase inhibitors
(TKIs) to induction and consolidation chemo-
therapy followed by allogeneic hematopoietic
stem-cell transplantation (alloHSCT) has yielded
. 90% complete remission (CR)1 and up to
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60% 5-year overall survival (OS) rates.2-4 TKIs have also permitted
de-escalation of chemotherapywithout loss of response or event-free
survival in older patients, and deep molecular responses may be
achieved in some patients.4 A retrospective analysis in the post-
transplantation setting has shown that use of prophylactic TKIs is
associated with a signiﬁcantly lower incidence of relapse among
patients with Ph1 ALL.5 However, relapse remains clinically chal-
lenging and is frequently associated with resistance substitutions in
the ABL kinase domain, particularly within the threonine 315
residue (T315I).6,7 Although alternative TKIs for salvage therapy
may be effective in some patients,8,9 remission is short.10,11 In the
ﬁrst-line setting and in the context of alloHSCT, minimal residual
disease (MRD), as assessed by reverse transcription quantitative
polymerase chain reaction (RT-qPCR), may provide additional
prognostic information for relapse.12-14 There is no current evidence
of long-term survival mediated by TKIs after relapse.11 Sequential
TKI exposure can permit emergence of compound mutations that
eventually confer resistance to all TKIs.15-17 Relapse can also occur
without detection of BCR-ABL1mutations, suggesting that there are
kinase-independent pathways to leukemic cell survival and pro-
liferation. Therefore, alternative approaches beyond kinase in-
hibition that increase the potential for achieving CR and longer OS
are needed in relapsed/refractory (R/R) Ph1 ALL.
Blinatumomab is a bispeciﬁc T-cell engager antibody con-
struct that is designed to direct cytotoxic T cells to CD19-
expressing B cells.18 A large phase II study conﬁrmed anti-
leukemia activity and tolerability of blinatumomab in adults with
R/R Ph– ALL and reported 43% CR or CR with partial hematologic
recovery (CRh), 82% MRD response, and relapse-free survival
(RFS) of 5.9 months.19 Patients with Ph1 ALL are distinct from
those with Ph–ALL and often have different baseline demographics
that may have a signiﬁcant impact on clinical outcomes. Here, we
evaluated the efﬁcacy and tolerability of single-agent blinatumo-
mab in patients with R/R Ph1 ALL who progressed after or were
intolerant to a second-generation or later TKI.
PATIENTS AND METHODS
Patients
This was an open-label, single-arm, multicenter, phase II study of
blinatumomab in adults with R/R Ph1 ALL at 19 European and US centers.
Eligible adults (age $ 18 years) had Ph1 B-precursor ALL, had relapsed
after or were refractory to at least one second-generation or later TKI
(dasatinib, nilotinib, bosutinib, ponatinib), or were intolerant to second-
generation or later TKIs and intolerant or refractory to imatinib. The
Philadelphia chromosome was detected by cytogenetics, ﬂuorescence
in situ hybridization, and/or BCR-ABL1 PCR at individual study sites.
Additional eligibility requirements included . 5% bone marrow blasts as
determined by a central laboratory and an Eastern Cooperative Oncology
Group status # 2. Key exclusion criteria were alloHSCT within 12 weeks
before the start of blinatumomab treatment, active acute or chronic (grade
2 to 4) graft-versus-host disease, systemic treatment of graft-versus-host
disease within 2 weeks before treatment start, history or presence of
clinically relevant CNS pathology, active CNS ALL, and isolated extra-
medullary disease. Any TKI therapy, antitumor therapy other than bli-
natumomab, chronic systemic high-dose corticosteroid therapy, or other
immunosuppressive therapies were prohibited during treatment. Each
center’s institutional review board or ethics committee approved the study;
all patients provided written informed consent.
Study Procedures
Patients received blinatumomab as a continuous intravenous infusion at
ﬁxed stepwise doses (9 mg/day in week 1 of cycle 1 followed by 28 mg/day
thereafter).19,20 Each treatment cycle included 4 weeks of continuous in-
travenous infusion followed by a 2-week treatment-free interval. Patients
received two initial cycles of blinatumomab to induce remission. CR was
deﬁned as # 5% bone marrow blasts, platelets . 100,000/mL, and absolute
neutrophil count. 1,000/mL; CRhwas deﬁned as# 5%bonemarrow blasts,
platelets. 50,000/mL, and absolute neutrophil count . 500/mL. If CR/CRh
was achieved, the patient could receive up to three additional cycles of bli-
natumomab as consolidation therapy, unless alloHSCTwas scheduled earlier.
To reduce tumor burden and cytokine release syndrome (CRS), pa-
tients with a high baseline blast count as determined by a local laboratory
(. 50% bone marrow blasts or $ 15,000/mL peripheral blast count) re-
ceived prephase treatment with dexamethasone 10mg/m2 per day (for up to
5 days) up to a maximum of 24 mg/day (absolute). All patients were given
dexamethasone 20 mg intravenously 1 hour before each cycle and dose step
and within 1 hour before restarting treatment for dose interruptions. For
dose interruptions that resulted from a neurologic event, patients received
dexamethasone at least 24 mg/day, with stepwise reductions over 4 days.
Intrathecal chemoprophylaxis (eg, methotrexate 12 to 15 mg, cytarabine
40 mg, and dexamethasone 4 mg or equivalent) was required before ini-
tiation of treatment and at the end of treatment cycles. Detailed descriptions
regarding blinatumomab dose modiﬁcations, interruptions, and discon-
tinuation are provided in the Appendix (online only).
Hematologic and molecular responses were assessed by bone marrow
aspirate or biopsy on day 29 of each cycle by using a central reference
laboratory. MRD response was determined by BCR-ABL1 quantiﬁcation
only for patients achieving CR/CRh. Complete MRD response was deﬁned
as no detectable BCR-ABL1 transcripts by allele-speciﬁc real-time qPCR
with an internal ABL ampliﬁcation control, as established by a central
laboratory (LabCorp, Burlington, NC; assay sensitivity $ 1025; 0.00%
BCR-ABL1/ABL1). p190 and p210 designation was based on determination
of e1a2 (p190) or b2a2/b3a2 (p210) transcript levels from RT-qPCR
performed on pretreatment bonemarrow aspirates.21 Adverse events (AEs)
and serious AEs, which were recorded from treatment start until at least
30 days after treatment end, were graded according to the Common
Terminology Criteria for Adverse Events (CTCAE) v4.0.22
Statistical Methods
The primary end point was the proportion of patients who achieved
CR/CRh during the ﬁrst two cycles of blinatumomab treatment. Sample
size was calculated for a Simon’s two-stage design23 based on a one-sided
type I error of 0.025 and a power of 90% to detect the effective response
rate assumption of $ 30% over an ineffective treatment rate of # 10%.
Major secondary end points included MRD response rate during the
ﬁrst two cycles of treatment, RFS, OS, and alloHSCTafter blinatumomab-
induced remission. RFS was measured from the time of ﬁrst CR/CRh to
hematologic or extramedullary relapse or death resulting from any cause.
OS was measured from the time of ﬁrst blinatumomab dose to death
resulting from any cause. Kaplan-Meier methods were used to estimate
probability of RFS and OS over time; OS among MRD responders was
evaluated using the landmark analysis approach to minimize bias that
patients must survive to their ﬁrst MRD assessment to be included.
RESULTS
Patient Characteristics
Between January 3, 2014, and May 20, 2015, 45 patients were
enrolled and treated with blinatumomab. Median age was 55 years
(range, 23 to 78 years). Forty-four percent of patients had relapsed
after prior alloHSCT. Median baseline bone marrow blast per-
centage was 80% (range, 6% to 98%). At data cutoff (May 20,
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2015), 23 patients (51%) remained in the study (21 were in follow-
up, and two were still receiving treatment).
Eighty-four percent of patients had received $ 2 prior TKIs;
51% had received prior ponatinib (third-generation TKI; Table 1).
All patients were either refractory to (56%), had relapsed on
(33%), or exhibited disease progression after (11%) their prior TKI
therapy; no patient had TKI intolerance listed as the reason for
discontinuation of their prior TKI therapy. One patient had ALL
resistant to imatinib and was never exposed to a second-generation
or later TKI (protocol deviation).
Fifty-nine percent of patients had additional cytogenetic
abnormalities. A subset of patients (n = 10) had both p190 and
p210 transcripts, although in all patients, p210 was 2.1- to 3.5-log
higher and thus designated as p210. Of 37 patients evaluable for
TKI mutational analysis, 46% had ABL1 kinase domain mutations,
including the T315I mutation (27%; Table 1).
Response
Themedian number of blinatumomab cycles received was two
(range, one to ﬁve). Thirty-six percent (95% CI, 22% to 51%) of
patients (n = 16) achieved CR/CRh within the ﬁrst two cycles, with
most patients (n = 14) achieving CR (Table 2). Among evaluable
responders in cycle 1, 10 achieved CR before initiation of a second
cycle, two achieved CRh, and two were without hematologic
recovery. Two patients had inevaluable responses at the end of cycle 1;
however, both achieved blast clearance by the end of cycle 2 (one with
CR and one with CRh). Among nonresponders or those with
progressive disease at the end of cycle 1, two achieved CR with
incomplete hematologic recovery (CRi) at the end of cycle 2. The one
patient who never received a second-generation or later TKI (pro-
tocol deviation) did not respond to treatment. Twelve (86%) of the 14
CR responders and both patients with CRh also achieved a complete
MRD response; the remaining two responders had persistent
measurable MRD and relapsed during subsequent cycles of therapy.
Patients achieved responses to blinatumomab regardless of
prior TKI therapy: 47% had three or more prior TKIs and 35% had
received prior ponatinib. Similarly, responses were also observed
regardless of ABL1 kinase domain mutational status (Fig 1). Spe-
ciﬁcally, among the 10 patients with the T315I mutation (nine of
whom had received prior ponatinib), four (40%) responded, with all
four CR/CRh responders also achieving a complete MRD response.
Subgroup analyses of response showed no statistically sig-
niﬁcant differences based on collected baseline features, including
age and prior therapies, but the largest difference in median
CR/CRh response was observed between the subgroups of , 50%
and$ 50% bone marrow blasts at baseline (64% [95% CI, 31% to
89%] and 27% [95% CI, 13% to 44%], respectively; Fig 1).
Survival
Median RFSwas 6.7months (95%CI, 4.4 toNE [not estimable]
months), with a median follow-up of 9.0 months. Median RFS
among the 14 patients who achieved a complete MRD response was
6.8 months (95% CI, 4.4 to NE months) with a median follow-up
of 9.0 months, which was similar to that of the entire CR/CRh
responder patient population; RFS was not signiﬁcantly impacted
when censoring for alloHSCT (Fig 2A). No difference in median
RFS was observed between responders younger than age 55 years
(5.5 months; 95% CI, 3.6 to NE months) and adults age 55 years or
older (6.7months; 95%CI, 3.8 toNEmonths).Of the 16 responders,
seven (44%) were alive without relapse, eight (50%) had relapsed
with a median time to relapse of 6.7 months (95% CI, 4.4 to NE
months), and one patient died in CR after alloHSCT (133 days after
achieving CR). Of the patients who had relapsed, three had relapsed
during treatment (including two CR responders who did not achieve
a complete MRD response), two relapsed without receiving
alloHSCT, and three relapsed after receiving alloHSCT.
Median OS was 7.1 months (95% CI, 5.6 to NE months) with or
without censoring for alloHSCT (Fig 2B), with a median follow-up of
8.8months. Using a landmarkOS analysis (landmark time point at the
end of cycle 2 of blinatumomab treatment), median OS was not
reached for the 18 patients who achieved a complete MRD response,
with amedian follow-up of 5.3months. AmongMRDnonresponders,
the median OS was 3.9 months (95% CI, 3.0 to NE months).
alloHSCT
Of the 16 CR/CRh responders, seven (44%) proceeded
to alloHSCT, including four who remained in continuous
Table 1. Patient Demographic and Clinical Characteristics at Baseline
Characteristic
Patients (N = 45)
No. %
Sex
Male 24 53
Female 21 47
Median age, years (range) 55 (23-78)
Age group, years
18 to , 55 22 49
$ 55 23 51
Cytogenetics and molecular analyses*
Philadelphia chromosome and other
cytogenetic abnormalities
22/38 58
ABL1 kinase domain mutations 17/37 46
T315I mutation 10/37 27
No. of prior TKI treatments†
1 7 16
2 21 47
3 13 29
4 4 9
Prior TKI‡ 45 100
Imatinib 25 56
Dasatinib 39 87
Nilotinib 16 36
Ponatinib 23 51
Prior alloHSCT
Yes 20 44
No 25 56
Bone marrow blasts (central review)
, 10% 2 4
10% to , 50% 9 20
50% to , 75% 6 13
$ 75% 28 62
Abbreviations: ABL1, Abelson murine leukemia viral oncogene homolog 1;
alloHSCT, allogeneic hematopoietic stem-cell transplantation; TKI, tyrosine ki-
nase inhibitor.
*Philadelphia chromosome was detected by cytogenetics/metaphase spread,
ﬂuorescence in situ hybridization, or BCR-ABL1 polymerase chain reaction.
Numerators indicate the number of patients in each subgroup, and denominators
indicate the number of evaluable patients tested by a speciﬁc methodology.
†One patient had acute lymphoblastic leukemia that was resistant to imatinib
and was never exposed to a second-generation or later TKI (protocol deviation).
‡Prior TKI use was not mutually exclusive.
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blinatumomab-induced remission without other antileukemia
therapy and three who received blinatumomab with other anti-
leukemia therapy. Of the latter three patients, one received other
anticancer therapy prior to alloHSCT and remained in remission,
and two had relapsed before proceeding to alloHSCT. The 100-day
mortality was 25% (one death) among the four patients who
received alloHSCT while in blinatumomab-induced remission
(Table 2). One responder received a second alloHSCT after
blinatumomab-induced remission.
AEs
Among the 45 patients who received blinatumomab, the most
common treatment-emergent AEs included pyrexia (58%), febrile
neutropenia (40%), and headache (31%) (Table 3). Thirty-seven
patients (82%) had grade $ 3 treatment-emergent AEs, the most
frequent of which were febrile neutropenia (27%), thrombocy-
topenia (22%), and anemia (16%). Twenty patients (44%) had
grade $ 3 treatment-emergent AEs that were considered possibly
related to blinatumomab (per investigator’s assessment), most
commonly febrile neutropenia and increased levels of alanine
aminotransferase (11% each). Thirty-three patients (73%) had
grade 3 AEs, and 16 patients (36%) had grade 4 AEs. Five patients
(none of whom achieved CR/CRh) had fatal AEs: multiorgan
failure (age 55 years), infection (sepsis, age 40 years; septic shock,
age 33 years), cerebral hemorrhage (age 25 years), and respiratory
failure (age 42 years). One fatal AE (septic shock) was considered
treatment-related by the investigator. This patient had disease
persistence and died 13 days after protocol-directed discontinu-
ation of blinatumomab.
CRS occurred in three patients (all grade 1 or 2), but none
of the CRS events resulted in treatment discontinuation or in-
terruption. Twenty-one patients (47%) experienced neurologic
events, most commonly paresthesia (13%), confusional state
(11%), dizziness (9%), and tremor (9%; Table 3). Three patients
had grade 3 neurologic events (aphasia, hemiplegia, and nervous
system disorder or depressed level of consciousness). However,
only one patient required treatment interruption (aphasia). No
patients had grade 4 or 5 neurologic events. All but one of the
grade 3 neurologic events resolved, with a maximum duration of
15 days.
DISCUSSION
In this primary analysis of a phase II study in adults with heavily
pretreated R/R Ph1 ALL, treatment with single-agent blinatu-
momab resulted in a 36% CR/CRh rate within the ﬁrst two cycles,
Table 2. Response Outcomes During the First Two Cycles and Transplantation Realization
Outcome Patients (n/N1)* Proportion (%) 95% CI
Primary end point
CR/CRh during the ﬁrst two cycles 16/45 36 22 to 51
Philadelphia chromosome and other cytogenetic
abnormalities
10/22 45 24 to 68
ABL1 kinase domain mutations 6/17 35 14 to 62
T315I mutation 4/10 40 12 to 74
p190 BCR/ABL1 isoform† 10/26 39 20 to 59
p210 BCR/ABL1 isoform† 5/16 31 11 to 59
No. of prior TKI therapies
1 1/7 14 , 1 to 58
2 7/21 33 15 to 57
$ 3 8/17 47 23 to 72
Prior ponatinib 8/23 35 16 to 57
Prior alloHSCT 5/20 25 9 to 49
Age 18 to , 55 years 8/22 36 17 to 59
Age $ 55 years 8/23 35 16 to 57
Bone marrow blasts , 50% 7/11 64 31 to 89
Bone marrow blasts $ 50% 9/34 27 13 to 44
Secondary end points
Best response during the ﬁrst two cycles
CR 14/45 31 18 to 47
CRh 2/45 4 1 to 15
Complete MRD response‡ 14/16 88 62 to 98
alloHSCT after blinatumomab-induced remission§ 4/16 25 7 to 52
Age 18 to , 55 years 2/8 25 3 to 65
Age $ 55 years 2/8 25 3 to 65
100-day post-transplant mortality rate§ 1/4 25 4 to 87
Abbreviations: alloHSCT, allogeneic hematopoietic stem-cell transplantation;ABL1, Abelsonmurine leukemia viral oncogene homolog 1;BCR, breakpoint cluster region;
CR, complete remission; CRh, CR with partial hematologic recovery; MRD, minimal residual disease; TKI, tyrosine kinase inhibitor.
*n/N1, number of responders/total number of patients with evaluable data under each category.
†Isoform designation was determined by MRD status at baseline by using reverse transcription quantitative polymerase chain reaction (PCR) on pretreatment bone
marrow aspirates. A subset of patients (n = 10) had both p190 and p210 transcripts, although in all of these patients, p210was 2.1- to 3.5-log higher; the transcripts were
thus assigned a designation of p210. Further details are provided in Patients and Methods.
‡Among CR/CRh responders only; includes all four CR/CRh patients with the T315I mutation.
§For patients who received alloHSCT during blinatumomab-induced remission without other antileukemia therapy. Complete MRD response was deﬁned as no
detectable PCR ampliﬁcation of BCR-ABL1 genes (sensitivity $ 10-5) as assessed by a central laboratory.
1798 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Martinelli et al
Downloaded from ascopubs.org by UCL Library Services on July 14, 2017 from 128.041.061.019
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
with 88% of responders also achieving a complete MRD response.
Median RFS and OS were 6.7 and 7.1 months, respectively. AEs
were consistent with those previously observed for blinatumomab
in the setting of R/R Ph– ALL. As predicted by the mechanism of
action of blinatumomab, these data demonstrate that hematologic
and molecular responses were independent of BCR-ABL1 status,
including the presence of the T315I mutation. More than one third
of patients (38%) had at least one BCR-ABL1 mutation, including
10 with the T315I mutation, a recognized negative prognostic
factor, even for treatment with ponatinib and/or alloHSCT.24,25 In
fact, the T315I mutation along with additional kinase domain
mutations have been associated with poor treatment responses and
outcomes, possibly as a result of increased genetic heterogeneity
among leukemic subclones that may lead to TKI-based drug
resistance.26
All patients had heavily pretreated R/R Ph1 ALL, with
nearly half (47%) having failed two prior TKI treatments and
one third (38%) having failed three or more prior TKI treat-
ments; 62% had $ 75% blasts at baseline; or 44% had relapsed
after alloHSCT. Notably, these data show that the proportion of
patients who achieved CR/CRh was in line with that reported for
less heavily pretreated populations or those in the Ph– setting
(36% v 43% in Ph– ALL), with similar or better response du-
ration than that observed with TKI therapies.27-29 Although not
statistically signiﬁcant, a higher CR/CRh rate was observed in
patients with a low (, 50%) blast percentage at baseline
compared with patients who had a high ($ 50%) blast per-
centage (Fig 1), a trend consistent with blinatumomab treat-
ment in the Ph– setting.19 Interestingly, the ﬁve patients younger
than age 35 years did not respond, which may be the result of
higher disease burden (eg, $ 50% bone marrow blasts) and
disease aggressiveness (eg, shorter median time from initial
diagnosis to treatment and from ﬁrst prior alloHSCT to relapse)
among these patients. Given the very small number of patients,
however, this is highly exploratory and speculative. Tumor load
may be a marker of disease aggressiveness of leukemia, which
may or may not be modiﬁed by cytoreduction. Alternatively, any
potential association between tumor load and response may
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Fig 1. Overall responses (complete remission/complete remission with partial hematologic recovery [CR/CRh]) during the ﬁrst two treatment cycles among prespeciﬁed
patient subgroups. The dashed line represents the point estimate for CR/CRh for the entire patient population, and the box size indicates the relative population weight.
n/N1, number of responders/total number of patients with evaluable responses within each category. alloHSCT, allogeneic hematopoietic stem-cell transplantation; ECOG,
Eastern Cooperative Oncology Group; TKI, tyrosine kinase inhibitor.
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reﬂect an unfavorable effector-to-target ratio, which could be
amenable to intervention. In a randomized trial of blinatu-
momab versus standard chemotherapy for R/R Ph– ALL, the
survival beneﬁt of blinatumomab was observed even among
patients with high bone marrow blasts.30
Therapeutic options for patients with R/R Ph+ ALL are scarce
and restricted to untargeted therapies such as combination che-
motherapy, interferon-alpha, or omacetaxine mepesuccinate,
which provide only short-term and primarily hematologic re-
sponses with poor cytogenetic efﬁcacy.31-33 For eligible patients
with Ph1 ALL and the T315I mutation, alloHSCTremains the best
treatment option, providing acceptable OS rates and, in some
cases, long-term control of the malignancy. Because of its TKI-
independent mechanism of action, blinatumomab can overcome
the T315I resistance mechanism to induce directed immune-
mediated cell death of Ph1 blasts. However, it is unknown
whether BCR-ABL12independent signaling in patients with ALL
that is refractory to TKIs may also predispose patients to be re-
sistant to blinatumomab treatment. Here, response rates to bli-
natumomab and RFS were found to be similar between younger
(age younger than 55 years) and older (age 55 years or older)
adults, which was also reported for Ph– ALL,34 suggesting a beneﬁt
for older adults who are typically ineligible for alloHSCT or have
increased comorbidities. Moreover, blinatumomab induced
complete MRD responses in 88% of Ph1 patients who achieved
CR/CRh, suggesting that blinatumomab is an effective bridge to
transplantation.
Because duration of response to TKIs is short in Ph1 ALL,35
consolidative alloHSCT remains the standard of care for eligible
patients, and achievement of CR andMRD response is desirable for
stem-cell transplantation. Ph1 patients, such as those treated in
this trial, tend to be older and likely ineligible for myeloablative
conditioning regimens.36 However, these patients may be eligible
to receive reduced-intensity conditioning regimens, and recent
reports suggest that MRD status has prognostic relevance in this
setting, presumably because of greater reliance on graft-versus-
leukemia effects and less reliance on cytoreduction after the
conditioning regimen.8,13,37 Recurrence of leukemia after trans-
plantation in patients with incomplete MRD response also raises
the necessity for rigorous and standard MRD monitoring of these
patients, as is currently done in pediatric and cooperative studies in
the adult ALL setting.38,39
In summary, these data demonstrate efﬁcacy of single-agent
blinatumomab in R/R Ph1 ALL, suggesting a possible future role in
Ph-like ALL and combination therapies with TKIs for this disease
setting.
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Appendix
METHODS
Dose modiﬁcations, interruptions, and discontinuation. Blinatumomab was temporarily or permanently reduced to 9 mg/day, if
necessary, on the basis of the investigator’s judgment for reasons of safety. Patients with dose reductions had the option to receive
the higher dose level of 28 mg/day once the adverse event (AE; except for neurologic events) resolved to at least grade 1 for$ 7 days.
Dexamethasone pretreatment was required for all patients who restarted blinatumomab treatment. For patients with signs of
cytokine release syndrome, oral or intravenous dexamethasone 8 mg was given three times per day for up to 3 days and reduced
stepwise over 4 days. For grade$ 3 cytokine release syndrome, tumor lysis syndrome, and disseminated intravascular coagulation/
coagulopathy, treatment was interrupted until the event resolved to at least grade 1. For grade $ 3 infections, blinatumomab was
interrupted until the infection was adequately controlled or resolved per investigator opinion, and then allowed to restart at the
lowest starting dose (9 mg/day). Blinatumomab was permanently discontinued for grade 4 AEs that were possibly related to
blinatumomab or for AEs that lasted 2 weeks or longer. For grade$ 3 neurologic events, blinatumomab was stopped immediately,
and the patient was assessed by physical examination, vital signs, and safety laboratories. To exclude potential infectious causes,
cerebrospinal ﬂuid was collected and assessed by cytology, cell count, B- and T-cell measurements, and viral studies. For grade 3
neurologic events or serious AEs leading to treatment interruption, treatment was restarted no earlier than 72 hours after stopping
infusion but within 2 weeks.
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